Leading stem cell and exosome therapy research blog by Cell La Vie, Bangkok. Clinical insights, cost breakdowns, and regenerative treatment guides.
A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.
Read More »Our Bangkok clinic explores how MSC therapy is helping COPD patients breathe easier — reducing inflammation, reactivating lung stem cells, and improving quality of life.
Read More »Japan approved the world’s first MSC therapy for spinal cord injury in 2018. Here’s what six years of real-world data and 2026 mechanism research tell us about where MSC therapy for SCI actually stands.
Read More »Planning a trip to Bangkok for stem cell therapy involves more than just scheduling your procedure date. International patients need to know: What does the post-treatment recovery week actually look like? Whether receiving intravenous (IV) infusions or targeted joint injections, the vast majority of patients experience minimal downtime. Here is a clear, day-by-day breakdown of what […]
Read More »Diabetic ED, post-prostatectomy ED, PDE5 non-responders — here’s what 2026 trials and clinical experience show for stem cell therapy: who is a candidate, what the procedure looks like, what it costs, and what to expect.
Read More »One of the most frequent clinical questions patients ask before undergoing regenerative treatment is whether receiving donor stem cells requires blood typing (ABO and Rh factor matching) or cross-matching, similar to a blood transfusion or organ transplant. If you have blood type O-negative, A-positive, or AB-positive, do you need donor cells that match your exact […]
Read More »MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.
Read More »Eight 2026 studies detail how MSC exosomes inhibit ferroptosis, deliver sustained paracrine signaling via hydrogels, and improve LVEF in rat MI models. Here is what translational researchers need to know before the first Phase 2 exosome trial reads out.
Read More »Discover the groundbreaking potential of MSC-derived exosomes in revolutionizing Rheumatoid Arthritis immunotherapy. Learn about novel nanoplatforms and their mechanism of action.
Read More »2026 medical update on MSC therapy for diabetic foot ulcers: M2 macrophage polarization, EXO-miR3671 angiogenesis, hydrogel delivery, UC-MSC vs ADSC head-to-head, 47-RCT meta-analysis, and cost-effectiveness vs amputation in Thailand.
Read More »2026 Q3 update on allogeneic vs autologous MSC: head-to-head trial data, donor-age impact, 2026 manufacturing advances, when each is preferred, the cost picture, and FAQ for patients in Thailand and Asia-Pacific.
Read More »